These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10992997)

  • 21. Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study).
    Arntz HR; Agrawal R; Wunderlich W; Schnitzer L; Stern R; Fischer F; Schultheiss HP
    Am J Cardiol; 2000 Dec; 86(12):1293-8. PubMed ID: 11113401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.
    Hunt D; Young P; Simes J; Hague W; Mann S; Owensby D; Lane G; Tonkin A
    Ann Intern Med; 2001 May; 134(10):931-40. PubMed ID: 11352694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.
    Nagata-Kobayashi S; Shimbo T; Matsui K; Fukui T
    Int J Cardiol; 2005 Sep; 104(2):213-23. PubMed ID: 16168816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cost-effectiveness of atorvastatin in the early treatment of acute coronary syndromes in Germany based on the MIRACL study].
    Lange AP; Szucs TD
    Med Klin (Munich); 2004 Sep; 99(9):500-5. PubMed ID: 15372179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.
    Prosser LA; Stinnett AA; Goldman PA; Williams LW; Hunink MG; Goldman L; Weinstein MC
    Ann Intern Med; 2000 May; 132(10):769-79. PubMed ID: 10819699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial.
    Avorn J; Benner J; Ford I; Ganz DA; Gaw A; Glynn RJ; Jackson J; Lagaay AM; Schneeweiss S; Walley T; Wang PS;
    Control Clin Trials; 2002 Dec; 23(6):757-73. PubMed ID: 12505250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria.
    Lim SS; Vos T; Peeters A; Liew D; McNeil JJ
    Med J Aust; 2001 Nov; 175(9):459-64. PubMed ID: 11758073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain.
    Gómez-Gerique JA; Casciano R; Stern L; Rejas J
    Eur J Health Econ; 2004 Oct; 5(3):278-84. PubMed ID: 15714350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels.
    Tsevat J; Kuntz KM; Orav EJ; Weinstein MC; Sacks FM; Goldman L
    Am Heart J; 2001 May; 141(5):727-34. PubMed ID: 11320359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maximizing the cost-effectiveness of lipid-lowering therapy.
    Jacobson TA; Schein JR; Williamson A; Ballantyne CM
    Arch Intern Med; 1998 Oct; 158(18):1977-89. PubMed ID: 9778197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis.
    Boettiger DC; Newall AT; Chattranukulchai P; Chaiwarith R; Khusuwan S; Avihingsanon A; Phillips A; Bendavid E; Law MG; Kahn JG; Ross J; Bautista-Arredondo S; Kiertiburanakul S
    J Int AIDS Soc; 2020 Jun; 23 Suppl 1(Suppl 1):e25494. PubMed ID: 32562359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W; Forder P; Simes J; Hunt D; Tonkin A;
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease.
    Erickson KF; Japa S; Owens DK; Chertow GM; Garber AM; Goldhaber-Fiebert JD
    J Am Coll Cardiol; 2013 Mar; 61(12):1250-8. PubMed ID: 23500327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction.
    Elliott WJ; Weir DR
    Am J Health Syst Pharm; 1999 Sep; 56(17):1726-32. PubMed ID: 10512503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
    Martens LL; Guibert R
    Clin Ther; 1994; 16(6):1052-62; discussion 1036. PubMed ID: 7697684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of applying the Cholesterol and Recurrent Events (CARE) study protocol in Hong Kong.
    Chau J; Cheung BM; McGhee SM; Lauder IJ; Lau CP; Kumana CR
    Hong Kong Med J; 2001 Dec; 7(4):360-8. PubMed ID: 11773670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pravastatin and coronary heart disease.
    Bloom JM
    Lancet; 2001 Mar; 357(9261):1040. PubMed ID: 11293615
    [No Abstract]   [Full Text] [Related]  

  • 39. Statin lipid-lowering therapy for acute myocardial infarction and unstable angina: efficacy and mechanism of benefit.
    Wright RS; Murphy JG; Bybee KA; Kopecky SL; LaBlanche JM
    Mayo Clin Proc; 2002 Oct; 77(10):1085-92. PubMed ID: 12374252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid-lowering for prevention of coronary heart disease: what policy now?
    Ul Haq I; Ramsay LE; Pickin DM; Yeo WW; Jackson PR; Payne JN
    Clin Sci (Lond); 1996 Oct; 91(4):399-413. PubMed ID: 8983865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.